» Articles » PMID: 10515857

Posttranslational Processing of the Thrombopoietin Receptor is Impaired in Polycythemia Vera

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1999 Oct 9
PMID 10515857
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Recently, we demonstrated a marked reduction in the expression of the thrombopoietin receptor, Mpl, in polycythemia vera (PV) platelets and megakaryocytes using an antiserum against the Mpl extracellular domain. To further examine this abnormality, we raised an antibody to the Mpl C-terminus. Immunologic analysis of PV platelets with this antiserum confirmed the reduction in Mpl expression. However, the C-terminal antiserum detected 2 forms of Mpl in PV platelets in contrast to normal platelets, in which a single form of Mpl was detected by both the extracellular domain and C-terminal antisera. Two-dimensional gel electrophoresis studies with isoelectric focusing in the first dimension identified normal platelet Mpl as an 85 to 92 kD protein with an isoelectric point (pI) of 5.5. PV platelets contained an additional 80 to 82 kD Mpl Mpl isoform with a pI of 6.5. Analysis of Mpl expressed by the human megakaryocytic cell line, Dami, showed 2 isoforms similar to those found in PV platelets suggesting a precursor-product relationship. Digestion of Dami cell and normal platelet lysates with neuraminidase converted the more acidic Mpl isoform to the more basic one, indicating that the 2 isoforms differed with respect to posttranslational glycosylation. Furthermore, in contrast to normal platelet Mpl, PV platelet Mpl was susceptible to endoglycosidase H digestion, indicating defective Mpl processing by PV megakaryocytes. The glycosylation defect was specific for Mpl, as 2 other platelet membrane glycoproteins, glycoprotein IIb and multimerin, were processed normally. Importantly, the extent of the PV platelet Mpl glycosylation defect correlated with disease duration and extramedullary hematopoiesis.

Citing Articles

Myeloproliferative Neoplasms: Challenging Dogma.

Spivak J J Clin Med. 2024; 13(22).

PMID: 39598101 PMC: 11595126. DOI: 10.3390/jcm13226957.


The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia.

Karantanos T, Teodorescu P, Perkins B, Christodoulou I, Esteb C, Varadhan R Sci Adv. 2022; 8(7):eabl8952.

PMID: 35179961 PMC: 8856621. DOI: 10.1126/sciadv.abl8952.


The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN.

Spivak J, Moliterno A Front Oncol. 2021; 11:641613.

PMID: 33777803 PMC: 7987816. DOI: 10.3389/fonc.2021.641613.


Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.

Spivak J, Merchant A, Williams D, Rogers O, Zhao W, Duffield A PLoS One. 2020; 15(6):e0232801.

PMID: 32479500 PMC: 7263591. DOI: 10.1371/journal.pone.0232801.


Multiple Roles of Glycans in Hematological Malignancies.

Pang X, Li H, Guan F, Li X Front Oncol. 2018; 8:364.

PMID: 30237983 PMC: 6135871. DOI: 10.3389/fonc.2018.00364.